HRG2101

HRG2101 is a small molecule drug developed by Jiangsu Hengrui Pharmaceuticals. It acts as a cytokine modulator and specifically inhibits transforming growth factor beta 1 (TGF-β1). The drug was primarily investigated for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases. Its mechanism of action involves modulation of cytokines and inhibition of TGF-β1, which plays a key role in fibrotic processes. Clinical development included phase 1 trials using oral inhalation to assess safety, tolerability, pharmacokinetics, and bioavailability compared to pirfenidone tablets. Development has been discontinued after phase 1[1][2].